STAT May 2, 2024
Ed Silverman

In a boost for Gilead Sciences, the California Supreme Court agreed to review a contentious legal theory that thousands of HIV patients have used in a closely watched case to argue drugmakers can be held negligent for failing to develop a medicine.

Earlier this year, a state appeals court ruled the company could be held liable for halting further development of an HIV medicine that was safer than an HIV drug it was already selling. Back in 2004, Gilead explained its decision by maintaining the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
STAT+: NVIDIA’s Kimberly Powell touts progress on AI in drug discovery
Big pharma ignores low-cost migraine solution
Sanders: Weight loss drug could bankrupt healthcare system
J&J Joins Chase for Hot Immunology Target With $850M Proteologix Acquisition
Going beyond A, B & O: Thermo Fisher unveils DNA test for the rarest blood types

Share This Article